Sir, The most prevalent plasmid-mediated quinolone resistance mechanism in Enterobacteriaceae is the AAC(6 0 )-Ib-cr enzyme.
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It provides low-level resistance that by itself does not exceed the clinical breakpoint for susceptibility, but nonetheless facilitates selection of higher-level resistance during treatment and makes infection harder to treat. 4 We have recently used MALDI-TOF MS to detect the AAC(6 0 )-Ib-cr enzyme in Enterobacteriaceae by visual inspection of the mass spectra of the acetylation reaction that yields an increase of 43 Da in the mass of the fluoroquinolones ciprofloxacin and norfloxacin. 5 The aim of this study was to automate data analysis and establish a simplified and reliable detection algorithm that enables quantification of the acetylation in relation to enzyme activity.
In a preliminary step to establish the cut-off for positivity, we tested a collection of 81 previously studied isogenic Escherichia coli control strains (all derived from E. coli ATCC 25922) carrying combinations of four chromosomally mediated quinolone resistance mechanisms (including modifications in gyrA and parC or marR deletion), plasmid-mediated qnr and AAC(6 0 )-Ib-cr enzyme, or the plasmid-mediated qepA2 efflux pump (Table S1 , available as Supplementary data at JAC Online). 5 Of the 81 isolates, 10 were AAC(6 0 )-Ib-cr producers. In the second part of the study, we evaluated the optimized quantitative approach in a series of 122 blinded clinical isolates (one per patient and epidemiologically unrelated) obtained in January 2017 from hospitalized patients (Complejo Hospitalario Universitario A Coruña) with urinary tract infections. Isolates were selected from among E. coli and Klebsiella pneumoniae phenotypically expressing an ESBL. 3 The isolates were further characterized in relation to the presence of the AAC(6 0 )-Ib-cr enzyme. 6 The MALDI-TOF MS acetylation reaction assay was performed as described by Oviaño et al. 5 To establish the working concentration, the isogenic E. coli control strains were submitted to evaluation with ciprofloxacin and norfloxacin concentrations of 0.25 and 0.50 mg/mL.
The presence of the AAC(6 0 )-Ib-cr enzyme was determined by automated analysis of the spectra performed with an in-house program, MALDI Biotyper PeakShift Prototype (Bruker Daltonik GmbH), written in the freely available software package R. 7, 8 The spectra were first baseline subtracted and normalized to the maximum peak. Automated peak selection was performed and peaks belonging to the corresponding antibiotic drug and the respective acetylation products were labelled, with a tolerance of 0. 5 Mass peaks were selected with a resolution .300 and a signal-to-noise threshold of 4. The AUC was determined for each spectrum. The relative acetylation or the logIQ (logarithm intensity quantification) was then calculated as the ratio of the AUCs, by using the formula logIQ " log (sum [AUC acetylated peak intensities ])/(sum [AUC non-acetylated peak intensities ]). The a-cyano-4-hydroxycinnamic acid peak at 379.02 Da was used for calibration, with a tolerance of 1 Da. A cut-off value for the logIQ value for determining the activity of the AAC(6 0 )-Ib-cr enzyme was established for both ciprofloxacin and norfloxacin. The blinded clinical isolates were analysed under the conditions previously optimized for the isogenic control strains and data evaluation was performed using the MALDI Biotyper PeakShift Prototype.
Clear separation of the isogenic E. coli controls strains into two groups was achieved for both ciprofloxacin and norfloxacin acetylation reactions when using 0.2 mg/mL. A mean logIQ value of ,#1.5 was obtained for all isolates not carrying the AAC(6 0 )-Ib-cr Clinical isolates carrying the AAC(6 0 )-Ib-cr resistance determinant yielded an average ciprofloxacin logIQ value of 0.06, whilst for norfloxacin the average logIQ value was 0.32 (Table S2) . Clear differentiation between AAC(6 0 )-Ib-cr-producing isolates and nonproducing isolates was found after an incubation time of 30 min ( Figure 1) . Use of the previously established cut-off value of logIQ .#0.5 for positivity yielded 100% sensitivity and specificity with both ciprofloxacin and norfloxacin. The results of the resistance assay for detecting the AAC(6 0 )-Ib-cr enzyme were 100% in agreement with the results of the molecular characterization of the isolates. The positive and negative predictive values of the MALDI-TOF-based assay for detecting the AAC(6 0 )-Ib-cr enzyme were also 100%. The variability regarding the logIQ values could not be related to differences in the level of expression of the resistance mechanism either at the molecular level or in terms of the MIC (data not shown).
The MALDI-TOF MS model created using the MALDI Biotyper PeakShift Prototype software for automated interpretation of mass spectra has shown excellent performance. This is especially important as the mass peaks yielded by the antibiotic and its acetylated product appear in the same spectrum, as previously demonstrated by Oviaño et al. 5 and Pardo et al. 9 The quantification ensures that all logIQ values above the cut-off correspond to positive acetylation of the antibiotic, thus reducing the risk of misclassification of isolates due to lack of experience in the visual interpretation of a mass spectrum. Use of the software also reduces the intra-and inter-observer variability of the assay and provides standardized results. Use of MALDI-TOF MS with the automated interpretation of the spectra led us to conclude that use of norfloxacin as a resistance marker in MS will enhance acetylation by the isolates. We therefore recommended use of this antibiotic for detection of the AAC(6 0 )-Ib-cr resistance determinant in clinical practice.
In conclusion, MALDI-TOF MS is an outstanding method for detecting AAC(6 0 )-Ib-cr activity in clinical samples. The method is easy to perform and is not time-consuming, as analytical results can be obtained in ,1 h. Sir, HIV capsid (CA) plays an essential role in multiple stages of the viral replication cycle, but it remains an unexplored target for ART. Previous in vitro studies have described a novel class of exquisitely potent and metabolically stable HIV capsid inhibitors (CAIs).
1 Recently, preclinical studies have revealed a highly potent CAI, GS-CA1, with an EC 50 of 140 pM, which is active against all major HIV-1 group M clades. 2 In vitro resistance selection experiments were performed with GS-CA1 and identified five amino acid substitutions in CA protein that independently confer resistance to GS-CA1: L56I, M66I, Q67H, N74D and A105E, all located at the GS-CA1 binding site in CA. 2 The aim of this study was to assess the prevalence of CA nucleotide substitutions previously described as being associated with in vitro resistance to the HIV-1 CAI GS-CA1 in antiretroviralnaive patients using ultra-deep sequencing technology at baseline and at time of virological failure (VF) in patients receiving a firstline PI-based regimen.
In an observational single-centre cohort, we assessed all antiretroviral-naive patients initiating a first-line regimen including two NRTIs and one PI (i.e. darunavir or atazanavir boosted with ritonavir) between January 2012 and March 2015. VF was defined as two consecutive plasma viral load (VL) values .50 copies/mL following virological suppression or as the absence of reaching VL ,50 copies/mL 6 months after antiretroviral initiation. All the patients gave their written informed consent to have their medical chart recorded in the electronic medical record system Nadis Ultra-deep sequencing of the CA region was assessed at baseline in 137 patients and at time of VF in 14 patients experiencing VF. HIV-1 RNA was extracted from 400 lL of plasma using the EZI Virus Mini Kit v. 2.0 V R (Qiagen, Hilden, Germany). First, a 1926 bp fragment of the gag gene was amplified from viral RNA using the PCR SuperScript TM III One-Step RT-PCR System with Platinum V R Taq High Fidelity (Thermo Fisher, Waltham, MA, USA), according to the manufacturer's instructions and using the following primers from Gall et al.:
3 Pan-HIV-1_1F (5 0 -AGCCYGGGAGCTCTCTG) and Pan-HIV-1_1R (5 0 -CCTCCAATTCCYCCTATCATTTT). A 1819 bp fragment was then amplified by a second-round of PCR using the primers: GAGPCRNEST_F (5 0 -TAAAGCTTGCCTTGAGTGC) and GAGPCRNEST_R (5 0 -TACTGTATCATCTGCTCCTG). Ultra-deep sequencing was performed using Illumina MiSeq technology (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. CA sequences were analysed using Geneious software v. 9.0.4 (https://www.gene ious.com). 4 Only mutations above 2% were retained. CA ultra-deep sequencing was successful at antiretroviral initiation in 132 samples of the 137 tested (96.4%). The distribution of HIV-1 subtypes was as follows: 42 (31.8%) subtype B, 48 (36.4%) CRF02_AG and 42 (31.8%) other 'non-B' subtypes. 
